Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 16;13(6):601-609.
doi: 10.1159/000539381. eCollection 2024 Dec.

Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma

Junichi Shindoh  1   2 , Yusuke Kawamura  3 , Keiichi Akahoshi  4 , Masaru Matsumura  1 , Satoshi Okubo  1 , Norio Akuta  3 , Minoru Tanabe  4 , Norihiro Kokudo  5 , Yoshiyuki Suzuki  3 , Masaji Hashimoto  1
Affiliations

Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma

Junichi Shindoh et al. Liver Cancer. .

Abstract

Introduction: Introduction of new systemic therapies for hepatocellular carcinoma (HCC) has led to the development of new oncological criteria of resectability for the resectability of HCC. This study was aimed at validating the prognosticating ability and clinical utility of the resectability classification based on the novel criteria in real-world clinical practice.

Methods: This study was conducted in 1,822 patients who had undergone curative resection for HCC (population 1) and 107 patients with unresectable disease who had received lenvatinib therapy (population 2). Patients were classified into three groups according to the novel oncological criteria for resectability (R, resectable; BR1, borderline resectable 1; and BR2, borderline resectable 2), and the prognosticating ability and clinical utility of this classification based on the novel criteria were examined.

Results: Multivariate analysis confirmed that classification of the patients according to the oncological resectability criteria was significantly correlated with the overall survival (OS) (BR1: hazard ratio [HR], 1.88; 95% CI, 1.38-2.55; BR2: HR, 4.12; 95% CI, 3.01-5.65) and recurrence-free survival (BR1: HR, 1.86; 95% CI, 1.44-2.41; BR2: HR, 3.62; 95% CI, 2.71-4.82) in population 1. In population 2, the resectability classification was correlated with the rates of successful additional intervention (surgery, transarterial chemoembolization, or radiotherapy) (BR1 65.7% vs. BR2 42.3%, p = 0.023) and curative-intent conversion surgery (BR1 17.1% vs. BR2 4.2%, p = 0.056) after lenvatinib therapy, and was also predictive of the OS (HR, 1.96; 95% CI, 1.13-3.38 for BR2 [vs. BR1]) and time-to-treatment failure (HR, 1.81; 95% CI, 1.04-3.17 for BR2 [vs. BR1]).

Conclusion: The resectability classification based on the novel oncological criteria for resectability showed acceptable prognosticating ability in both surgically and medically treated populations with advanced HCC.

Keywords: Consensus statement; Hepatocellular carcinoma; Resectability; Surgery; Systemic therapy.

PubMed Disclaimer

Conflict of interest statement

Junichi Shindoh and Yusuke Kawamura receive honoraria from Eisai Pharmaceutical Co., Ltd.

Figures

Fig. 1.
Fig. 1.
Adjust Kaplan-Meier curves stratified by the oncological criteria for resectability of HCC in population 1. a OS. b RFS.
Fig. 2.
Fig. 2.
Adjust Kaplan-Meier curves stratified by the oncological criteria for resectability of HCC in population 2. a OS. b TTF.
See this image and copyright information in PMC

References

    1. Shindoh J, Kawamura Y, Kobayashi Y, Kobayashi M, Akuta N, Okubo S, et al. . Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021;28(12):7663–72. - PubMed
    1. Itoh S, Toshida K, Morita K, Kurihara T, Nagao Y, Tomino T, et al. . Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. Int J Clin Oncol. 2022;27(11):1725–32. - PubMed
    1. Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Tominaga L, et al. . Efficacy of the combination of systemic sequential therapy and locoregional therapy in the long-term survival of patients with BCLC stage C hepatocellular carcinoma. Cancers. 2023;15(15):3789. - PMC - PubMed
    1. Zhu XD, Huang C, Shen YH, Ji Y, Ge NL, Qu XD, et al. . Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 2021;10(4):320–9. - PMC - PubMed
    1. Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. . Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117–27. - PubMed

LinkOut - more resources